Key Takeaways:
Everest Medicines (1952.HK) saw its largest shareholder, CBC Group, increase its stake with a purchase of 600,500 shares for approximately HK$19.2 million between May 20 and May 21.
The transaction, executed at an average price of HK$31.91 per share, was disclosed in a company announcement. "The board interprets these purchases as a clear vote of confidence in the company’s future growth and strategic direction," the company said in a statement.
This latest acquisition is part of a larger trend of insider buying. Since December 2025, CBC Group and company directors have collectively purchased more than 3.062 million shares on the open market, investing a total exceeding HK$113.8 million. The company has not disclosed what percentage of total outstanding shares these purchases represent.
The consistent buying by its principal shareholder provides a strong signal of internal confidence in the biopharmaceutical firm's valuation and long-term prospects. Investors will be watching to see if this insider accumulation translates to positive momentum for the stock, which closed down 2 percent at HK$31.84 on May 21. The next catalyst for the company will be its upcoming earnings report, expected in August.
This article is for informational purposes only and does not constitute investment advice.
